Verubecestat (MK-8931) is a potent, selective, structurally unique BACE inhibitor with Ki of 2.2 nM and 0.38 nM for BACE1 and BACE2, respectively.
Verubecestat (MK-8931) displays high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D.
Verubecestat (MK-8931) reduces plasma, cerebrospinal fluid (CSF), and brain concentrations of Aβ40, Aβ42, and sAPPβ.
Verubecestat (MK-8931) is well tolerated and produces reductions in Aβ40, Aβ42, and sAPPβ in the CSF of both healthy human subjects and AD patients in clinical evaluation.
